Beyond Drug Discovery: The Nanotechnology Molecular Optimization (NMO) Benchmark
Quick summary
arXiv:2606.30170v2 Announce Type: replace-cross Abstract: Generative molecular design is shaped by simple proxy benchmarks for drug-like properties and models pretrained on large pharmaceutical datasets. This combination yields strong benchmark metrics but limits transferability to domains structurally distinct from drug discovery. To overcome this limitation and drive discovery toward real, scientifically grounded targets, we introduce the Nanotechnology Molecular Optimization (NMO) Benchmark, which bridges machine learning (ML) and quantum materials science. NMO acts simultaneously as a rigo
Key takeaways
- arXiv:2606.30170v2 Announce Type: replace-cross Abstract: Generative molecular design is shaped by simple proxy benchmarks for drug-like properties and models pretrained on large pharmaceutical datasets.
- This combination yields strong benchmark metrics but limits transferability to domains structurally distinct from drug discovery.
- To overcome this limitation and drive discovery toward real, scientifically grounded targets, we introduce the Nanotechnology Molecular Optimization (NMO) Benchmark, which bridges machine learning (ML) and quantum materials science.
Why it matters
The value of this work lies as much in how it was tested as in the claim itself. Sample design, baselines, uncertainty and replication help separate a laboratory result from real-world impact.
Member comments